Home LiteratureArticle Details
PMID: 32446214 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Staging and grading of oral squamous cell carcinoma: An update.

Oral oncology ·Vol. 107 ·2020-00-00 ·Pages 104799

Almangush A, Mäkitie AA, Triantafyllou A, de Bree R, Strojan P, Rinaldo A, Hernandez-Prera JC, Suárez C, Kowalski LP, Ferlito A, Leivo I

Abstract

Oral squamous cell carcinoma (OSCC) is a common malignancy of the head and neck region. OSCC has a relatively low survival rate and the incidence of the disease is increasing in some geographic areas. Staging and grading of OSCC are established prerequisites for management, as they influence risk stratification and are the first step toward personalized treatment. The current AJCC/UICC TNM staging (8th edition, 2017) of OSCC has included significant modifications through the incorporation of depth of invasion in the T stage and extracapsular spread/extranodal extension in the N stage. Further modifications for AJCC 8 have been suggested. On the other hand, the World Health Organization (WHO) classification (4th edition, 2017) still endorses a simple, differentiation-based histopathologic grading system of OSCC (despite its low prognostic value) and ignores factors such as tumor growth pattern and dissociation, stromal reactions (desmoplasia, local immune response), and tumor-stroma ratio. The various controversies and possible developments of the current staging and grading criteria of OSCC are briefly discussed in this update together with possible applications of artificial intelligence in the context of screening and risk stratification.

Keywords
Grading Oral squamous cell carcinoma (OSCC) Prognosis Staging
MeSH Terms
Carcinoma, Squamous Cell Female Humans Male Mouth Neoplasms Neoplasm Grading/methods Neoplasm Staging/methods Prognosis
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Almangush Alhadi
Department of Pathology, University of Helsinki, Helsinki, Finland; Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Institute of Biomedicine, Pathology, University of Turku, Turku, Finland; Faculty of Dentistry, University of Misurata, Misurata, Libya. Electronic address: alhadi.almangush@helsinki.fi.
Mäkitie Antti A
Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Otorhinolaryngology, Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Finland; Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden. Electronic address: antti.makitie@helsinki.fi.
Triantafyllou Asterios
Department of Pathology, Liverpool Clinical Laboratories and School of Dentistry, University of Liverpool, Liverpool, UK. Electronic address: A.Triantafyllou@liverpool.ac.uk.
de Bree Remco
Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands. Electronic address: r.debree@umcutrecht.nl.
Strojan Primož
Department of Radiation Oncology, Institute of Oncology, Ljubljana, Slovenia. Electronic address: pstrojan@onko-i.si.
Rinaldo Alessandra
University of Udine School of Medicine, Udine, Italy. Electronic address: alessandra.rinaldo@uniud.it.
Hernandez-Prera Juan C
Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA. Electronic address: Juan.Hernandez-Prera@moffitt.org.
Suárez Carlos
Instituto de Investigacion Sanitaria del Principado de Asturias and (CIBERONC), ISCIII, Oviedo, Spain; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, Oviedo, Spain.
Kowalski Luiz P
Head and Neck Surgery and Otorhinolaryngology Department, A C Camargo Cancer Center, Sao Paulo, Brazil; Head and Neck Surgery, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil. Electronic address: lp_kowalski@uol.com.br.
Ferlito Alfio
Coordinator of the International Head and Neck Scientific Group, Padua, Italy. Electronic address: alfio.ferlito@uniud.it.
Leivo Ilmo
Institute of Biomedicine, Pathology, University of Turku, Turku, Finland. Electronic address: ilmo.leivo@utu.fi.
Conflict of Interest

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com